The use of targeted agents against key signaling kinases is transforming cancer treatment. Drugs such as Herceptin and Zelboraf have increased progression-free survival in breast cancer and melanoma respectively and are far from the only examples. However, the complexity of signaling pathway networks allows tumor cells to adapt under monotherapy using alternative pathways to maintain a proliferative phenotype. Such...
We believe that a longitudinal, Framingham-like study of 100,000 well individuals (hereafter termed the 100K project) and their dynamical data clouds could transform medicine by 1) providing scientifically validated metrics for wellness, 2) allowing one to study the earliest origins of disease in an individual and 3) allow one to follow the entire progression of a disease from its...
N-of-One inked an agreement with Belgian personalized medicine firm OncoDNA under which it will provide clinical interpretation for all of OncoDNA's next-generation sequencing (NGS) and other molecular tests for patients throughout Europe, the Middle East, and other parts of the world.
OncoDNA provides tumor profiling services designed to help medical doctors choose treatments and monitor tumor evolution. N-of-One's clinical interpretation,...
Next-generation sequencing (NGS) has been making tremendous strides in the research market and with Illumina’s recent launch of the HiSeq X Ten, we’ve essentially reached the $1,000 genome (notwithstanding quibbles over what exactly should be accounted for in the $1,000). With these advancements, the pull to adapt NGS for the clinical market has gotten stronger. The first examples of...
While the first traffic light flashed 18 years before the first car was built, the rules of the road have long lagged behind technology where genetic testing is concerned, especially in distinguishing functional gene variants from those that cause disease.
That is starting to change as groups of researchers and clinicians hammer out guidelines for statistically rigorous and evidence-based clinical...
In 2009 Mark Boguski and colleagues published a paper entitled “Customized care 2020: how medical sequencing and network biology will enable personalized medicine.” In the paper the authors described a model incorporating these pathways, annotation of disease networks and drug targets, and simulation of therapeutic interventions with virtual drugs or with combinations of them.
The pathology report of the future,...
Cancer Genetics said today it acquired Indian-based BioServe Biotechnologies for about $1.9 million, primarily in stock and other deferred payments, in a deal designed to help the buyer scale up its genetic analysis, bioinformatics, and manufacturing operations while capitalizing on clinical diagnostics and trial growth in India and the Asian market over recent years.
BioServe India will become a wholly...
The third issue of Clinical OMICs is available now! Check it out by clicking on the link below.
If a genetic variant is the origin and a disease the destination, the biochemical path between them may appear on a map of a sprawling genetic/metabolomic network. But that’s just the simplest imaginable use of such a map. Rather than think of a genetic/metabolomic map as a way to trace a single path, as though one were using a...
Like travelers who roam curious lands, oncologists who delve into tumor genetics may find themselves in need of local guides, experts who will put them on the right path. As far as oncologists are concerned, the right path is the one that leads to an effective therapy, but in difficult-to-treat cases, the path to the best treatment plan may...
